Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells

Paolo Paoletti, MD

Chief Executive Officer

Dr. Paoletti, was formerly the first appointed president of GSK Oncology, where he was responsible for championing an organisation of more than 2,000 professionals around the world dedicated to fighting the causes and impacts of cancer.  As the leader of the business unit, he had accountability for the overall oncology business within GSK and oversaw all activities from early drug discovery through clinical development, launch and life cycle management.

During his tenure at GSK, seven new medicines to treat different kinds of cancer were approved globally, generating annual sales of about US$2 billion. In particular, oncology products that have received respective US and EU approval under Dr. Paoletti’s leadership include Arranon/Atriance, Tykerb/Tyverb, Promacta/Revolade, Arzerra, Votrient, Tafinlar and Mekinist. In 2014, GSK sold the Oncology business for US$16 billion to Novartis in a complex 3 way transaction. Prior to join GSK, Dr. Paoletti was Vice President of Oncology Clinical Research at Lilly, where he developed ALIMTA (> US$ 2 Billion annual sales). Most recently Dr. Paoletti was Chief Executive Officer of Kesios Therapeutics Limited.

Dr. Paoletti has a degree in Medicine from the University of Pisa (Italy) where he was professor in Pulmonary Diseases and authored more than 300 publications.

Dr. Paoletti,  is currently a non-executive director for Genmab, PsiOxus Therapeutics (Chairman of the Board) and FORMA Therapeutics.